Search

Showing "11155" results for ""

ICAAC: Nevirapine and rifampicin can be safely used together

ICAAC: Moxifloxacin as effective as ethambutol in TB treatment

ICAAC: Early trials involving new GSK protease inhibitor have encouraging results

ICAAC: Nevirapine still present in breastmilk two weeks after last dose

ICAAC: Achillion reveals potential for once weekly dosing of nucleoside analogue

South African study finds many patients die waiting for treatment after enrolment into antiretroviral rollout programme

Improving the diagnosis of active TB in people with HIV

ICAAC: Pilot study shows dual protease inhibitor regimen as safe and effective as traditional two class HIV therapy

ICAAC: New treatment for lipid problems shows promise in HIV patients

ICAAC: TB patients with good CD4 cell counts can safely defer HIV treatment

ICAAC: Studies look at risk factors for cell changes in anus and cervix

ICAAC: Factors unrelated to HIV or side-effects of HIV treatment major cause of illness in French cohort

ICAAC: Viral load between six to 18 months predicts longer-term success of HIV therapy

ICAAC: Dividing Triomune tablets may result in inadequate doses for small children; liquid best

ICAAC: TMC114 shows further promise in second POWER study

Ugandan ART programme claims to reduce sexual risk taking and the risk of HIV transmission

ICAAC: Women who shed HSV in genitals shed more HIV

ICAAC: HCV only factor associated with liver problems in patients starting HIV treatment in 2004

Receive the latest HIV research and conference news

Showing "11155" results for ""

ICAAC: Nevirapine and rifampicin can be safely used together

ICAAC: Moxifloxacin as effective as ethambutol in TB treatment

ICAAC: Early trials involving new GSK protease inhibitor have encouraging results

ICAAC: Nevirapine still present in breastmilk two weeks after last dose

ICAAC: Achillion reveals potential for once weekly dosing of nucleoside analogue

South African study finds many patients die waiting for treatment after enrolment into antiretroviral rollout programme

Improving the diagnosis of active TB in people with HIV

ICAAC: Pilot study shows dual protease inhibitor regimen as safe and effective as traditional two class HIV therapy

ICAAC: New treatment for lipid problems shows promise in HIV patients

ICAAC: TB patients with good CD4 cell counts can safely defer HIV treatment

ICAAC: Studies look at risk factors for cell changes in anus and cervix

ICAAC: Factors unrelated to HIV or side-effects of HIV treatment major cause of illness in French cohort

ICAAC: Viral load between six to 18 months predicts longer-term success of HIV therapy

ICAAC: Dividing Triomune tablets may result in inadequate doses for small children; liquid best

ICAAC: TMC114 shows further promise in second POWER study

Ugandan ART programme claims to reduce sexual risk taking and the risk of HIV transmission

ICAAC: Women who shed HSV in genitals shed more HIV

ICAAC: HCV only factor associated with liver problems in patients starting HIV treatment in 2004

Receive the latest HIV research and conference news